仁济医院专家团队研究成果有望为胰腺癌免疫治疗提供新的策略及思路 - 2021年07月12日

Experts from Shanghai's Renji Hospital discovered a new subtype of cancer-associated fibroblasts that may be a good candidate for a biomarker for the effects of pancreatic cancer immunotherapy.

The discovery offers new targets and strategies for immunotherapy drug resistance in pancreatic cancer, experts said.

Pancreatic cancer is called the king of cancer due to its high malignancy and poor treatment effects. Its prevalence is rising in China and abroad, but there is no effective treatment. Immunotherapy, which has had good results in the treatment of other types of cancer, has had few positive effects in treating pancreatic cancer.